Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
Recurrence at 3 months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors
Urology, 07/02/09
Palou J et al. - In a trial to evaluate risk factors for disease progression in the frequent subgroup of Stage T1G2 (World Health Organization 1973) bladder tumors, it was found that in primary urothelial T1G2 bladder cancer, recurrence at 3 mos was the main prognostic factor related to progression. Additional factors were the association of carcinoma in situ (CIS) with the primary tumor and presence of high-grade disease and/or CIS at first recurrence.
Methods- 616 pts with Stage T1G2 were treated with transurethral resection and random bladder biopsies.
- Mean follow-up was 4.2 yrs.
- -Iindependent variables were multiplicity, association with carcinoma in situ (CIS), tumor size, tumor recurrence at 3 or 6 mos, tumor grade, and association with CIS at first recurrence.
- Dependent variable was progression to muscle-invasive disease.
- Progression to muscle-invasive disease was identified in 28 of 616 pts (4.5%).
- When considering recurrence at 3 mos, this factor was the principal prognostic factor, with a relative risk of 4.0, followed by presence of high-grade disease or CIS at first recurrence and CIS associated with the primary tumor.
- When considering recurrence at 6 mos, more prognostic factors were involved for progression, including as multiple tumors, CIS associated with primary tumor, recurrence at 6 mos, and presence of high-grade disease or CIS at the first recurrence.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group
Journal of Clinical Oncology, 10/19/09
Nonsteroidal anti-inflammatory drugs
Cancer, 10/16/09
Today in Urology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians
Annals of Internal Medicine, 10/20/09
Sponsor
Article Search
Sponsor


See Latest Articles


